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The morbidity and mortality that are associated 
with hepatitis B virus (HBV) infection have been 
overshadowed by the public health prominence 
of other infectious diseases, including human 
immunodeficiency virus (HIV) infection, tubercu-
losis, and malaria. There is a dawning realiza-
tion that the disease burden from HBV infection 
is increasing, despite the existence of an effective 
vaccine.1 The World Health Organization (WHO) 
estimates that chronic HBV infection results in 
a quarter million deaths each year in the coun-
tries that are eligible for Global Vaccine Alliance 
(GAVI) support or cofinancing.2 A positive status 
for hepatitis B e antigen (HBeAg) and a maternal 
HBV DNA level of more than 200,000 IU per 
milliliter are associated with an increased risk of 
perinatal HBV infection despite vaccination.3 In-
fection in the neonatal period and childhood re-
mains the leading source of new chronic infections 
and is a silent precursor to progressive disease. 
Thus, the prevention of neonatal and childhood 
infection by effective prophylaxis is crucial.
Schedules of either three or four doses are 
used for hepatitis B immunization, depending 
on government policy and national prevalence. 
Currently, HBV vaccination is most frequently 
administered as a pentavalent or hexavalent vac-
cine as part of the Expanded Program on Immu-
nization (EPI), typically in combination with vac-
cines against diphtheria, tetanus, pertussis, polio, 
and Haemophilus inf luenzae type B. The first dose 
of HBV vaccine is given at 6 weeks of age to en-
sure immunogenicity of the combination. Despite 
recommendations from the WHO, only 92 of 193 
countries (48%) report administering the vaccine 
at birth. In sub-Saharan Africa, the vaccine is 
currently administered at birth in 10% of neo-
nates, and only 11 of 47 countries in the WHO 
African region have introduced a regimen of vac-
cination at birth.4,5 As a result, an estimated 1% 
of newborns annually (>365,000 newborns in one 
model) are infected with HBV at birth in sub-
Saharan Africa; this is twice the incidence of 
HIV infection among infants in this region.6
Paradoxically, GAVI support for combination 
vaccines within an integrated EPI schedule has 
unwittingly but undesirably shifted thinking and 
policy away from HBV vaccination at birth. This 
gap in vaccine strategy is disadvantageous. Anti-
viral therapy for pregnant women in the third 
trimester is effective in reducing vaccine and 
immune globulin failure in children born to 
mothers with high levels of viremia, but the HBV 
DNA level cannot be ascertained in many low-
income countries.7
In this issue of the Journal, Jourdain et al.8 re-
port the results of a multicenter, double-blind trial 
of tenofovir disoproxil fumarate (TDF) versus 
placebo that was conducted in 17 public hospitals 
in Thailand. TDF and placebo were administered 
from 28 weeks of gestation to 2 months post par-
tum in 331 women who were positive for HBeAg 
and the hepatitis B surface antigen (HBsAg). The 
median HBV DNA level was 8.1 log10 IU per milli-
liter in the TDF group and 7.9 log10 IU per milli-
liter in the placebo group. At enrollment, 90% of 
the women in the TDF group and 87% of those 
in the placebo group had an HBV DNA level of 
more than 200,000 IU per milliliter. HIV-positive 
women were excluded. All the children were 
given HBV vaccine and hepatitis B immune 
globulin at birth. Remarkably, the median time 
of HBV vaccination was 1.2 hours after birth, 
and 4% of infants received vaccine after 4 hours. 
Four doses of HBV vaccine were thus adminis-
tered. A total of 2% of the infants in the placebo 
group (3 of 147 infants) and none of the infants in 
the TDF group were HBsAg-positive at 6 months 
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of age. The most frequent adverse event was an 
elevation in the alanine aminotransferase level 
in the mothers (18% in the TDF group and 15% 
in the placebo group).
Although this trial and other studies point to 
some value for antiviral prophylaxis in preventing 
mother-to-child transmission, this trial did not 
prove the superiority of TDF prophylaxis. The 
low rate of transmission in the placebo group 
(in contrast to previously reported data from Pan 
et al.7) implies a role for the administration of 
the HBV vaccine within hours after birth to re-
duce the risk of mother-to-child transmission 
without additional testing or antiviral therapy in 
mothers with high levels of viremia. Other fac-
tors that were not answered in this trial require 
understanding: these include the effect of vac-
cination in infants born to mothers coinfected 
with HBV and HIV, intrauterine transmission, 
HBV genotypes, and vaccine escape mutants. 
(HBV DNA levels in mothers with HBV–HIV co-
infection are typically higher than in mothers 
infected with only HBV; however, women with 
known HIV infection are given antiretroviral 
treatment, which also lowers HBV DNA levels, 
and thus the risk of mother-to-child transmis-
sion is, theoretically, reduced.)
Given these data, what is the way forward? 
Several strategies can reduce the incidence of 
mother-to-child transmission; whatever is feasible 
should be applied in various countries. Vaccina-
tion, particularly if delayed, may fail to protect 
infants born to mothers with high serum levels 
of HBV DNA or HBeAg; the current levels of 
evidence supporting antiviral therapy with TDF 
(or possibly lamivudine or telbivudine) to reduce 
levels of maternal HBV DNA during pregnancy 
have been accepted by the American Association 
for the Study of Liver Diseases, the European 
Association for the Study of the Liver, and the 
Asian Pacific Association for the Study of the 
Liver.9-11 Preventing the residuum of chronic neo-
natal infections requires testing for HBsAg and 
HBV DNA and antiviral treatment or, alternative-
ly, simple measures that bypass additional testing 
and treatment. It is necessary to analyze regional 
data to assess the requirements for implement-
ing vaccination at birth, including access to de-
liveries at institutions such as hospitals or birth 
centers, rates of skilled birth attendance, deliv-
ery in conditions that lack cold-chain refrigera-
tion in rural versus urban areas, and the training 
of otherwise-unskilled birth attendants to deliver 
monovalent HBV vaccine at the same time as 
the vaccines against polio and bacille Calmette–
Guérin.12 Importantly, the use of monovalent 
HBV vaccine would also require governmental 
or nongovernmental (e.g., GAVI) support. HBV 
vaccination at birth, despite the challenges for 
poverty-affected countries to deliver vaccination 
in rural and isolated locales, is feasible. A con-
joint mobilization of HIV services to serve per-
sons with chronic HBV infection is required. The 
trial by Jourdain et al. (which the authors con-
sider statistically “negative”) puts down an in-
triguing marker attesting to the possibility that 
rapidly phasing in the timely administration of a 
safe monovalent HBV vaccine within a few hours 
after birth could contribute to the interruption of 
mother-to-child transmission and avert prevent-
able HBV infections in childhood.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
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